Effect of anticoagulant/antiplatelet therapy on the development and progression of diabetic retinopathy

Jeng, Chi‐Juei; Hsieh, Yi‐Ting; Lin, Cheng‐Li; Wang, I‐Jong

doi:10.1186/s12886-022-02323-z

Cited by 5 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Основные препараты, используемые при начальных стадиях ДР, относятся к группам гипотензивных, гиполипидемических препаратов, предназначенных для контроля гипергликемии, ингибиторов калликреин-кининовой системы, НПВС, ГКС, а также антибиотиков и иммунодепрессантов [2,3]. В современной клинической практике установлено, что при лечении ДР перспективным направлением является использование антикоагулянтов [4].…”

unclassified

Regarding the Use of Direct-Acting Anticoagulants of Animal Origin in Diabetic Retinopathy

Vorobyeva,

Biryukov,

Frolov

et al. 2023

Oftalʹmologiâ

View full text Add to dashboard Cite

Relevance. Diabetic retinopathy occupies one of the leading places in the frame of blindness and low vision. The very first changes in the retina in diabetic retinopathy are disorders of microcirculation and blood supply in the small vessels of the macula. There are few effective drugs that can restore perfusion in the small retina’s vessels. In this connection, it is relevant to search for anticoagulants that allow restoring blood supply in the macular area in diabetic retinopathy in the early stages.The purpose. To analyze the research of a domestic direct-action anticoagulant from animals, a drug of the heparin group Pyavit, both in ophthalmology for diabetic retinopathy and in other fields of medicine. The analysis of publications on eLibrary and PubMed resources for the last 30 years was done, by the keywords: direct-acting anticoagulants, diabetic retinopathy, hirudins, hemodynamics, optical coherence tomography (OCT), hemostasis. The data on the study and application of the drug from its development to its use in diabetic retinopathy, retinal vascular pathology, and pregnancy was analyzed. Researchers have studied the importance of the salivary gland secretion of a medical leech, which is a regulator of the hemostasis system. In 1992 I.P. Baskova patented a new drug Pyavit, which is officially approved for use in medical practice (registration number No. 000363/02). Dosage regimen: 300 mg three times a day for 20 days, and repeat the course through 1–2 months. In ophthalmology, researchers have proven the positive effect of the drug on the retina in diabetic retinopathy with an improvement in visual acuity, retinal thickness according to objective indicators of optical coherence tomography, fluorescence angiography, and hemostasis system.Conclusion. The analysis of scientists’ research allows us to expand knowledge about the positive effect of the drug Piavit on the path of diabetic retinopathy. Based on this review, the authors plan to further study the drug, which will assess the importance and significance of improving microcirculation in the macular area of the retina using the anticoagulant Pyavit to preserve visual functions.

show abstract

unclassified

Regarding the Use of Direct-Acting Anticoagulants of Animal Origin in Diabetic Retinopathy

Vorobyeva,

Biryukov,

Frolov

et al. 2023

Oftalʹmologiâ

View full text Add to dashboard Cite

show abstract

Cost-effectiveness of diabetic retinopathy screening for newly diagnosed type 2 diabetic patients: A nationwide population-based propensity score-matched cohort study

Chung,

Kao,

Huang

et al. 2024

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

Prevalence and risk factors for diabetic retinopathy at diagnosis of type 2 diabetes: an observational study of 77 681 patients from the Swedish National Diabetes Registry

Sofizadeh,

Eeg-Olofsson,

Lind

2024

BMJ Open Diab Res Care

View full text Add to dashboard Cite

IntroductionTo assess the prevalence of diabetic retinopathy (DR) in persons with newly diagnosed type 2 diabetes (T2D) to understand the potential need for intensified screening for early detection of T2D.Research design and methodsIndividuals from the Swedish National Diabetes Registry with a retinal photo <2 years after diagnosis of T2D were included. The proportion of patients with retinopathy (simplex or worse) was assessed. Patient characteristics and risk factors at diagnosis were analyzed in relation to DR with logistic regression.ResultsIn total, 77 681 individuals with newly diagnosed T2D, mean age 62.6 years, 41.1% females were included. Of these, 13 329 (17.2%) had DR.DR was more common in older persons (adjusted OR 1.03 per 10-year increase, 95% CI 1.01 to 1.05) and men compared with women, OR 1.10 (1.05 to 1.14). Other variables associated with DR were OR (95% CI): lower education 1.08 (1.02 to 1.14); previous stroke 1.18 (1.07 to 1.30); chronic kidney disease 1.29 (1.07 to 1.56); treatment with acetylsalicylic acid 1.14 (1.07 to 1.21); ACE inhibitors 1.12 (1.05 to 1.19); and alpha blockers 1.41 (1.15 to 1.73). DR was more common in individuals born in Asia (OR 1.16, 95% CI 1.08 to 1.25) and European countries other than those born in Sweden (OR 1.11, 95% CI 1.05 to 1.18).ConclusionsIntensified focus on screening of T2D may be needed in Sweden in clinical practice since nearly one-fifth of persons have retinopathy at diagnosis of T2D. The prevalence of DR was higher in men, birthplace outside of Sweden, and those with a history of stroke, kidney disease, and hypertension.

show abstract

Effect of anticoagulant/antiplatelet therapy on the development and progression of diabetic retinopathy

Cited by 5 publications

References 53 publications

Regarding the Use of Direct-Acting Anticoagulants of Animal Origin in Diabetic Retinopathy

Regarding the Use of Direct-Acting Anticoagulants of Animal Origin in Diabetic Retinopathy

Cost-effectiveness of diabetic retinopathy screening for newly diagnosed type 2 diabetic patients: A nationwide population-based propensity score-matched cohort study

Prevalence and risk factors for diabetic retinopathy at diagnosis of type 2 diabetes: an observational study of 77 681 patients from the Swedish National Diabetes Registry

Contact Info

Product

Resources

About